Research ExplorerPublicationsKlinische Endpunkte in Real-World-Register-Studien: PRAEGNAN...

Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom

Standard

Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom. / Hartkopf, Andreas D.; Emons, Julius; Lux, Michael P.; Taran, Florin Andrei; Overkamp, Friedrich; Tesch, Hans; Titzmann, Adriana; Pöschke, Patrik; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W.; Belleville, Erik; Janni, Wolfgang; Fehm, Tanja N.; Kolberg, Hans Christian; Ettl, Johannes; Wallwiener, Diethelm; Schneeweiss, Andreas; Brucker, Sara Y.; Fasching, Peter A.

In: ONKOLOGE, Vol. 26, No. 6, 01.06.2020, p. 530-541.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Hartkopf, AD, Emons, J, Lux, MP, Taran, FA, Overkamp, F, Tesch, H, Titzmann, A, Pöschke, P, Lüftner, D, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Janni, W, Fehm, TN, Kolberg, HC, Ettl, J, Wallwiener, D, Schneeweiss, A, Brucker, SY & Fasching, PA 2020, 'Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom', ONKOLOGE, vol. 26, no. 6, pp. 530-541. https://doi.org/10.1007/s00761-020-00766-x

APA

Hartkopf, A. D., Emons, J., Lux, M. P., Taran, F. A., Overkamp, F., Tesch, H., Titzmann, A., Pöschke, P., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Janni, W., Fehm, T. N., Kolberg, H. C., Ettl, J., Wallwiener, D., Schneeweiss, A., ... Fasching, P. A. (2020). Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom. ONKOLOGE, 26(6), 530-541. https://doi.org/10.1007/s00761-020-00766-x

Vancouver

Hartkopf AD, Emons J, Lux MP, Taran FA, Overkamp F, Tesch H et al. Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom. ONKOLOGE. 2020 Jun 1;26(6):530-541. https://doi.org/10.1007/s00761-020-00766-x

Bibtex

@article{73b93f10db8343ce924ac67713daf919,
title = "Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk f{\"u}r Patientinnen mit fortgeschrittenem Mammakarzinom",
abstract = "Background: The therapeutic options for the individual patient with metastatic breast cancer are becoming more and more specific. Evidence for therapeutic recommendations from clinical trials is not available for all treatment situations and patient subgroups. This makes the collection and evaluation of real-world data meaningful. Methods and aims: To provide recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research Network (PREAGNANT) has been established to optimize the oncological quality of care in the advanced therapeutic setting. The main aim is to systematically record medical care of patients with metastatic breast cancer in real life including the therapeutic effects and side effects of the different treatment strategies, to monitor the quality of life changes during therapy, to identify patients who could participate in a clinical drug study and to enable a targeted therapy based on molecular structures of breast cancer patients. Conclusion: This article presents a summary of the PRAEGNANT network and sheds light on the question of the portability of the various endpoints from clinical trials into the real world treatment situation.",
keywords = "Artificial intelligence, Big data, Clinical decision-making, Evidence-based medicine, Information systems",
author = "Hartkopf, {Andreas D.} and Julius Emons and Lux, {Michael P.} and Taran, {Florin Andrei} and Friedrich Overkamp and Hans Tesch and Adriana Titzmann and Patrik P{\"o}schke and Diana L{\"u}ftner and Markus Wallwiener and Volkmar M{\"u}ller and Beckmann, {Matthias W.} and Erik Belleville and Wolfgang Janni and Fehm, {Tanja N.} and Kolberg, {Hans Christian} and Johannes Ettl and Diethelm Wallwiener and Andreas Schneeweiss and Brucker, {Sara Y.} and Fasching, {Peter A.}",
note = "Funding Information: Diese Studie wird gef?rdert von Forschungsgrants der Firmen Novartis, Celgene und Roche. Des Weiteren wird sie gef?rdert von TRR (Translational Research Ressources) der Frauenklinik des Universit?tsklinikums Erlangen. Publisher Copyright: {\textcopyright} 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = jun,
day = "1",
doi = "10.1007/s00761-020-00766-x",
language = "Deutsch",
volume = "26",
pages = "530--541",
journal = "ONKOLOGE",
issn = "0947-8965",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom

AU - Hartkopf, Andreas D.

AU - Emons, Julius

AU - Lux, Michael P.

AU - Taran, Florin Andrei

AU - Overkamp, Friedrich

AU - Tesch, Hans

AU - Titzmann, Adriana

AU - Pöschke, Patrik

AU - Lüftner, Diana

AU - Wallwiener, Markus

AU - Müller, Volkmar

AU - Beckmann, Matthias W.

AU - Belleville, Erik

AU - Janni, Wolfgang

AU - Fehm, Tanja N.

AU - Kolberg, Hans Christian

AU - Ettl, Johannes

AU - Wallwiener, Diethelm

AU - Schneeweiss, Andreas

AU - Brucker, Sara Y.

AU - Fasching, Peter A.

N1 - Funding Information: Diese Studie wird gef?rdert von Forschungsgrants der Firmen Novartis, Celgene und Roche. Des Weiteren wird sie gef?rdert von TRR (Translational Research Ressources) der Frauenklinik des Universit?tsklinikums Erlangen. Publisher Copyright: © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Background: The therapeutic options for the individual patient with metastatic breast cancer are becoming more and more specific. Evidence for therapeutic recommendations from clinical trials is not available for all treatment situations and patient subgroups. This makes the collection and evaluation of real-world data meaningful. Methods and aims: To provide recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research Network (PREAGNANT) has been established to optimize the oncological quality of care in the advanced therapeutic setting. The main aim is to systematically record medical care of patients with metastatic breast cancer in real life including the therapeutic effects and side effects of the different treatment strategies, to monitor the quality of life changes during therapy, to identify patients who could participate in a clinical drug study and to enable a targeted therapy based on molecular structures of breast cancer patients. Conclusion: This article presents a summary of the PRAEGNANT network and sheds light on the question of the portability of the various endpoints from clinical trials into the real world treatment situation.

AB - Background: The therapeutic options for the individual patient with metastatic breast cancer are becoming more and more specific. Evidence for therapeutic recommendations from clinical trials is not available for all treatment situations and patient subgroups. This makes the collection and evaluation of real-world data meaningful. Methods and aims: To provide recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research Network (PREAGNANT) has been established to optimize the oncological quality of care in the advanced therapeutic setting. The main aim is to systematically record medical care of patients with metastatic breast cancer in real life including the therapeutic effects and side effects of the different treatment strategies, to monitor the quality of life changes during therapy, to identify patients who could participate in a clinical drug study and to enable a targeted therapy based on molecular structures of breast cancer patients. Conclusion: This article presents a summary of the PRAEGNANT network and sheds light on the question of the portability of the various endpoints from clinical trials into the real world treatment situation.

KW - Artificial intelligence

KW - Big data

KW - Clinical decision-making

KW - Evidence-based medicine

KW - Information systems

UR - http://www.scopus.com/inward/record.url?scp=85083978542&partnerID=8YFLogxK

U2 - 10.1007/s00761-020-00766-x

DO - 10.1007/s00761-020-00766-x

M3 - SCORING: Review

AN - SCOPUS:85083978542

VL - 26

SP - 530

EP - 541

JO - ONKOLOGE

JF - ONKOLOGE

SN - 0947-8965

IS - 6

ER -